Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Medical Advances Get More Chances When Safety Issues Arise

Nov 19 2013

• By Bridget Silverman

Related Content

FDA “Regulatory Flexibility” On Accelerated Approval Must Result In Some Withdrawals

Apr 15 2013

<em>Avandia</em> Review Endorsement Aided By Good Data, Cultural Shift On Safety

Jun 17 2013

Pfizer Trovan Suspension Recommended In EU; Distribution Limited In U.S.

Jun 14 1999

Will CV Verdicts For <em>Onglyza</em>, <em>Nesina</em> Cause FDA To Change Its Tune On Antidiabetic Safety?

Sep 09 2013

Can <em>Iclusig</em> Return To Market? Ariad Sees Path Through Restricted Distribution REMS

Nov 04 2013

What Innovation Crisis? First-In-Class Drug Approvals Stable For Almost 25 Years, FDA Says

Oct 15 2013

Related Companies

ARIAD Pharmaceuticals, Inc.

Bristol Myers Squibb Company

AstraZeneca PLC

Pfizer Inc.

GSK plc

Takeda Pharmaceutical Co. Ltd.

Genentech, Inc.

Abbott

Otsuka Holdings Co., Ltd.

Bristol Myers Squibb Company

Merck & Co., Inc.

Prometheus Laboratories Inc.

Biogen, Inc.

Elan Corporation

Additional Topics

Regulation Safety BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window